Supplementary data shows body weight changes in xenograft models treated with SHP2 inhibitor and combination therapies, suggesting enhanced therapeutic effects.
Supplementary Figure S4. Body weight change of KRASG12C inhibitor resistance models. A-B. Body weight change of NCI-H1373 GlecirasibR (A) and NCI-H1373 SotorasibR (B) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean ± SEM was shown.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: